Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - lyf til veikindi öndunarvegi sjúkdómum, - fasenra er ætlað sem bæta á viðhald meðferð í fullorðinn sjúklinga með alvarlega eósínófíl asma ekki nægilega stjórnað þrátt fyrir hár-skammt andað krefur plús langverkandi beta örvum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - bezlotoxumab - enterocolitis, pseudomembranous - Ónæmiskerfið sera og mótefni, - zinplava er ætlað til að koma í veg fyrir endurtekna clostridium difficile sýkingu (cdi) hjá fullorðnum sem eru í mikilli hættu á að endurtekna cdi.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

navamedic asa - cefotaximum natríum - stungulyfsstofn, lausn - 1 g

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - veira, lifandi dregið úr, mislingum, veirum, lifandi dregið, hettusótt, veira, lifandi dregið úr, rauðum hundum, veirum, lifandi dregið úr, varicella - chickenpox; rubella; measles; mumps; immunization - bóluefni - proquad er ætlað til samtímis bólusetningu gegn mislingum, hettusóttum, rauðum hundum og varicella hjá einstaklingum frá 12 mánaða aldri. proquad getur verið gefið til einstaklingar frá 9 mánaða aldur við sérstakar aðstæður (e. , í samræmi við national bólusetningu báta, braust aðstæður, eða ferðast á svæðinu með hár tíðni mislinga.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - sykursýki, tegund 2 - lyf notuð við sykursýki - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eli lilly danmark a/s - insulin human - stungulyf, dreifa í áfylltum lyfjapenna - 100 a.e./ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.